An international team of researchers have isolated and analyzed genetically tuberculosis bacteria from several thousand patients from over a hundred countries. This analysis demonstrates that the
For the first time, a German Liver Foundation trial shows that the chronic hepatitis C drugs developed in the last years can also cure acute hepatitis C—even faster than the chronic disease. The trial
The antibiotic daptomycin is often the last-resort treatment of multidrug-resistant bacteria. Up to now, it has been unclear how the drug works. A new study conducted with the DZIF now sheds light on
The natural substance researcher Prof Rolf Müller has been awarded the 2016 PHOENIX Pharmaceutical Science Award worth 10,000 euro. Müller heads the Helmholtz Institute for Pharmaceutical Research
The University of Tübingen has established a DZIF professorship in Africa for the first time, funded by the DZIF and the Government of Gabon. Dr Ayola Akim Adegnika has been appointed, he is currently
The Max von Pettenkofer Institute of Ludwig Maximilian University of Munich (LMU) has been appointed German National Reference Centre for Retroviruses. With this, it assumes central networking tasks
The bacterium Helicobacter pylori is an important gut pathogen and the main cause of gastric ulcers and gastric cancer. As yet it was not clear, which mechanisms play a role in these secondary
Multidrug-resistant tuberculosis is continuously spreading. Treatment has many side effects, is costly and, above all, lengthy. Since May 2016, the World Health Organisation (WHO) has recommended a
Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by
Some HIV-infected – and untreated children – who do not develop AIDS, control the virus in a different way from the few infected adults who remain disease-free. Scientists at LMU´s Max von Pettenkofer
